Published: June 19, 2025

Brenus Pharma and InSphero have developed 3D tumor spheroids mimicking in vivo human colorectal cancer conditions and confirming STC-1010’s efficacy

June 19, 2025  - Zurich, Switzerland | Lisbon, Portugal

Brenus Pharma, a French biotech developing next-generation first-in-class immunotherapies, and InSphero, a Swiss leader in 3D cell-based assay technologies, presented promising data at the European Association for Cancer Research 2025 annual congress. These data confirm the use of 3D tumor spheroids for potency testing of STC-1010, Brenus’ lead candidate for colorectal cancer.

Developed through a European-funded collaboration with InSphero, the project led to the creation of ready-to-use vitrified 3D colorectal cancer spheroids. Tumor spheroids were obtained with colorectal tumor cell lines co-cultured with colorectal fibroblasts. The vitrification method preserves tumor morphology, stromal integrity, and viability after thawing of fresh tumor spheroid samples. This approach enables a more realistic evaluation of STC-1010’s therapeutic potential, with a model that more closely mimics real in vivo tumor conditions.

Previous results demonstrated that STC-1010 antigens were efficiently taken up and presented by monocyte-derived dendritic cells (mMo-DCs), leading to the activation of CD8+ T cells. These T cells induce robust apoptosis in both 2D and 3D CRC models and trigger the release of anti-tumor cytokines such as IFNγ and Granzyme B. These results confirm the translational relevance of 3D models and support the therapeutic potential of STC-1010 in targeting colorectal cancer.

Brenus Pharma & InSphero Statements

“This collaboration with InSphero has enabled us to assess the highly representative and scalable 3D model in our SGC platform. It’s a major step forward in our ability to assess potency and accelerate the development of STC-1010 and future candidates.” Benoit Pinteur, CSO of Brenus Pharma.

“We are proud to support Brenus with our cryopreserved 3D tumor models. This work illustrates how advanced in vitro systems can bring immunotherapies closer to clinical reality”, added Jan Lichtenberg, CEO of InSphero.

The collaboration was initiated in 2022 under the EUROSTARS program, co-financed by Bpifrance and Innosuisse, to support innovation in oncology through international R&D partnerships.

Other News

Dr. Madhu Nag appointed to SLAS board of directors from January 1, 2025
News

InSphero CSO Dr. Madhu Nag Appointed to SLAS Board of Directors

InSphero is proud to announce that Chief Scientific Officer, Dr. Madhu Nag, has been appointed as a member of the Society for Laboratory Automation and Screening (SLAS) Board of Directors, serving a three-year term starting January 1, 2025. Dr. Nag will also take on the role of Board Secretary.

Read More »
Scroll to Top

Your Success is Our Mission - Get in Touch

Fill in form below to contact our 3D in vitro experts

Sign up for our Newsletter

Get the latest news on 3D in vitro research

View resource

Fill in the form below to view this resource